Medication info
Verapine Tablets (Terbinafine Hydrochloride)

Verapine Tablets (Terbinafine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Terbinafine Hydrochloride›140.625mg / 1 tablet
Manufacturer / importer
Youngil Pharmaceutical Co., Ltd.
Appearance
White to off-white round tablets
Packaging
30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200607002 · Notified 2006.06.29 · Insurance code 649400920

Summary

Main use
Treatment of onychomycosis and cutaneous fungal infections (such as tinea pedis and tinea corporis), and tinea capitis
Who takes it
Adults · Children
Adult dose
Adults Administer terbinafine 125 mg twice daily or 250 mg once daily. The treatment duration according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Usually administer for 6 weeks~3 months. Infections of the fingernails or relatively small toenails, or in younger patients, may require a shorter treatment duration of 3 months or less. For toenail infections, 3 months is usually sufficient, but some patients may require 6 months or longer. Treatment may take longer in patients with slow nail growth. Patients with renal impairment For patients with creatinine clearance less than 50 mL/min, reduce the daily dose by 1/2.
Child dose
Administer to children aged 2 years or older. Since there is no experience with administration to children under 2 years of age, use is not recommended. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be given regularly for an appropriately prescribed duration. Body weight less than 20 kg (under 5 years): Administer 62.5 mg once daily. Because experience with administration is limited, the decision to administer should be made after considering the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): Administer 125 mg once daily. Body weight over 40 kg (over 12 years): Administer 250 mg once daily.

Ingredients

Manufacturer
Youngil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of onychomycosis and cutaneous fungal infections (such as tinea pedis and tinea corporis), and tinea capitis

  • Dermatophytosis
  • tinea pedis
  • tinea corporis
  • tinea cruris
  • onychomycosis
  • tinea capitis
View approved original text

This medication is used for the treatment of tinea pedis, tinea corporis, tinea cruris, and onychomycosis caused by dermatophytes in adults. It is also effective for treating tinea capitis in children. It helps improve skin fungal infections.

How to take

Adult dose

Adults Administer terbinafine 125 mg twice daily or 250 mg once daily. The treatment duration according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Usually administer for 6 weeks~3 months. Infections of the fingernails or relatively small toenails, or in younger patients, may require a shorter treatment duration of 3 months or less. For toenail infections, 3 months is usually sufficient, but some patients may require 6 months or longer. Treatment may take longer in patients with slow nail growth. Patients with renal impairment For patients with creatinine clearance less than 50 mL/min, reduce the daily dose by 1/2.

Child dose

Administer to children aged 2 years or older. Since there is no experience with administration to children under 2 years of age, use is not recommended. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be given regularly for an appropriately prescribed duration. Body weight less than 20 kg (under 5 years): Administer 62.5 mg once daily. Because experience with administration is limited, the decision to administer should be made after considering the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): Administer 125 mg once daily. Body weight over 40 kg (over 12 years): Administer 250 mg once daily.

Precautions

This medication is not recommended for patients with chronic liver disease or active liver disease. Liver function tests must be conducted before administration, and regular liver function tests should be performed during treatment. If symptoms of liver dysfunction appear, the medication should be discontinued immediately and medical advice sought. This drug can cause liver dysfunction and, rarely, serious liver failure, so caution is required. This medication should not be administered to individuals with allergic reactions, blood disorders, severe renal failure, infants under 2 years old, nursing mothers, or certain hereditary lactose intolerance patients. It should be used cautiously in patients with impaired kidney function, the elderly, and children weighing less than 20 kg. Serious rashes or allergic reactions may appear, so the skin condition should be closely monitored, and if abnormal signs occur, usage should be discontinued. Muscle pain or joint pain may frequently occur, and rarely serious issues due to muscle damage may arise; therefore, medical consultation should be sought immediately if symptoms occur. This medication may cause various side effects such as gastrointestinal disturbances, headaches, dizziness, and depression, which should be observed carefully. Caution is necessary when driving or operating machinery if dizziness or other symptoms occur. There are numerous drug interactions; thus, if other medications are being taken, it is essential to inform the doctor or pharmacist, as dose adjustments may be necessary when used in conjunction with some medications. Women who are pregnant or may become pregnant should use this medication cautiously, and nursing mothers should discontinue breastfeeding while using it. In cases of overdose, headaches, nausea, abdominal pain, and dizziness may occur, necessitating immediate medical attention for appropriate treatment. This medication should be kept out of reach of children, stored in a sealed container to prevent exposure to air or moisture, and kept at room temperature away from direct sunlight.

Side effects

Persistent nausea, loss of appetite, fatigue, vomiting, upper right abdominal pain, jaundice, dark urine, loose stools, biliary tract failure, hepatitis, bile stasis, jaundice, rash, skin itching, fever, nausea, vomiting, anorexia, lethargy, elevated γ-GTP, increased AST/ALT, elevated LDH, increased ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, subcutaneous bleeding, leukopenia, anemia, rash, itching, photosensitivity reaction, skin and mucous membrane syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, blistering dermatitis, psoriasis-like rash, exacerbation of psoriasis, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, elevated serum myoglobin, elevated urinary myoglobin, hypotension, dyspnea, chest tightness, urticaria, erythema, facial swelling, lymphangiectasia, abdominal distension, dyspepsia, mild abdominal pain, diarrhea, upper abdominal discomfort, thirst, glossitis, depression, anxiety, headache, taste disorders, dizziness, drowsiness, sensory abnormalities, sensory loss, decreased attention span, insomnia, elevated BUN, frequent urination, visual impairment, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, increased serum total cholesterol, elevated triglycerides, lethargy, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, decreased vision, hearing loss, auditory impairment, vasculitis, permanent anosmia, anosmia, hyposmia, drug rash with eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, increased serum creatine phosphokinase, headache, nausea, epigastric pain, dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air or moisture from entering, preferably at a temperature between 1 and 30 degrees Celsius. Proper storage maintains the medication's effectiveness and prevents deterioration.

Appearance and packaging

Appearance

White to off-white round tablets

Package unit

30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.